Katharina Lückerath

Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance

Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice

Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance

Is There a Role of Artificial Intelligence in Preclinical Imaging?

Fibroblast Activation Protein Inhibitor Theranostics

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer

Immune-Checkpoint Blockade Enhances²²⁵Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer

Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma

[⁶⁸Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [¹⁸F]FDG and laboratory values

⁶⁸Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma

[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience

First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma